NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Growth Rank : 0 (As of Jun. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals Growth Rank?

NeuroBo Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

NeuroBo Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Berkeley Street, Office 19th Floor, Boston, MA, USA, 02116

Website

https://www.neurobopharma.com

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Executives

James Patrick Tursi	director	106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth	officer: Acting Chief Financial Officer	C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker	officer: Interim CEO and President	C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc.	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim	director	C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Andrew I Koven	director	3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Na Yeon Kim	director, 10 percent owner	C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Richard Kang	director	9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland	director	C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price	officer: CEO and President	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Akash Bakshi	director, officer: SVP and COO	602 BAINBRIDGE STREET, FOSTER CITY CA 94404